CHICAGO--(BUSINESS WIRE)--Results from three-year interim analyses of two ongoing long-term clinical trials showed that small mean declines in lung function in diabetes patients who took Exubera® (insulin human [rDNA origin]) Inhalation Powder reversed when Exubera was discontinued. Upon re-initiation of Exubera, lung function changes similar to first time users of Exubera were observed. The studies also showed that patients on an Exubera regimen maintained blood sugar control and generally gained less weight over the three-year period than those on an injected insulin regimen. These data were presented today at the 67th Annual Scientific Sessions of the American Diabetes Association.
